This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Robert John Sheppard: Inventor in Pharmaceutical Research
Introduction
Robert John Sheppard is an inventor associated with Gothenburg, Sweden, and AstraZeneca AB. His patent work concerns compounds and pharmaceutical approaches related to prolyl endopeptidase fibroblast activation protein (FAP).
Latest Patents
Sheppard is associated with 1 patent: “N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides.” The patent describes compounds of Formula (I), their pharmaceutically acceptable salts, pharmaceutical compositions, and kits. It also covers using these compounds and salts to treat or prevent conditions mediated by FAP, as well as methods for manufacturing them.
Career Highlights
Sheppard’s listed invention reflects work in medicinal chemistry and pharmaceutical development, with a focus on potential FAP-related treatments. He is associated with AstraZeneca AB, a pharmaceutical company.
Collaborations
The provided information lists Maria Johansson and Jonas Brånalt as Sheppard’s coworkers. Their names appear alongside his professional association with AstraZeneca AB.
Conclusion
Robert John Sheppard’s recorded patent centers on pharmaceutical compounds and methods intended to address FAP-mediated conditions, highlighting his contribution to drug research and development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile